Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : National Institute for Health and Care Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Doses First Patient in Phase 2 Trial on COPD Muscle Weakness & Sarcopenia
Details : RJx-01 is a combination of galantamine and metformin, works by inhibiting AChE and acting as an allosteric modulator of nAChRs, being investigated for COPD-related muscle weakness.
Product Name : RJx-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2025
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : National Institute for Health and Care Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG1205
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The 26-week study was conducted in 68 randomised patients and demonstrated that the GLPG1205 treatment arm had a smaller decline in forced vital capacity (FVC). Notably, this study was not powered to show statistical significance.
Product Name : GLPG1205
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2020
Lead Product(s) : GLPG1205
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG1205
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737. GLPG2737 is a CFTR1 inhibitor which was shown to be well tolerated by patients in previous clinical trials.
Product Name : GLPG1205
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : GLPG1205
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable